NASDAQ$SHC
Sotera Health Company · Q4 2024 earnings
Q4 2024 earnings · · Before market open · Investor relations
Briefing
Sotera Health's Q4 2024 results were announced, with a decrease in net revenues and net income compared to the same period last year, alongside a decline in adjusted EBITDA and adjusted EPS.
Sotera Health reported a decrease in net revenues for the fourth quarter of 2024, falling by 6.5% to $290 million. Net income also decreased to $12 million, or $0.04 per diluted share, compared to $39 million, or $0.14 per diluted share, in the same quarter of the previous year. Adjusted EBITDA saw a decrease of 8.3% to $153 million, and Adjusted EPS was $0.21, a decrease of $0.02 per diluted share.
- Net revenues decreased by 6.5% to $290 million compared to Q4 2023.
- Net income was $12 million, or $0.04 per diluted share, down from $39 million, or $0.14 per diluted share, in Q4 2023.
- Adjusted EBITDA decreased by 8.3% to $153 million compared to the prior-year quarter.
- Adjusted EPS was $0.21, a decrease of $0.02 per diluted share compared to Q4 2023.
Headline financials
Revenue & EPS history
Sotera Health · Revenue · Quarterly
$290M
Revenue by segment
Sotera Health · $263M total across 3 segments · Q3 2023
- Sterigenics$168M+6.7%64.0%
- Nelson Labs$54.7M-2.1%20.8%
- Nordion$40.1M+14.3%15.2%
Forward guidance
Sotera Health provided its full-year 2025 outlook, including net revenues growth in the range of 4.0% to 6.0% on a constant currency basis and Adjusted EPS in the range of $0.70 to $0.76.
Tailwinds
- Net revenues growth in the range of 4.0% to 6.0%, on a constant currency basis.
- Adjusted EBITDA growth in the range of 4.5% to 6.5%, on a constant currency basis.
- Adjusted EPS in the range of $0.70 to $0.76.
- A weighted-average fully diluted share count in the range of 286 million to 287 million shares.
- Capital expenditures in the range of $190 million to $210 million.
Headwinds
- Foreign currency headwind to net revenues of approximately 2.25%.
- Foreign currency headwind to Adjusted EBITDA of approximately 2.50%.
- Interest expense in the range of $155 million to $165 million.
- Tax rate applicable to Adjusted Net Income in the range of 33.0% to 35.0%.
- The Company does not provide a reconciliation for non-GAAP financial measures on a forward-looking basis where it is unable to provide a meaningful or accurate calculation or estimation of reconciling items without unreasonable effort.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
-2.7%
Avg return
Earnings day
-3.0%
Avg return
5 days after
-2.4%
Avg return
30 days after
25%
6 / 24 earnings
Positive
+11.2%
Q2 2024
Best reaction
-15.9%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.3% | +2.6% | +1.2% | |
| Q4 2025 | -0.5% | -7.1% | -22.6% | |
| Q3 2025 | -1.1% | -5.6% | -0.3% | |
| Q1 2025 | +5.2% | +11.7% | +6.4% | |
| Q4 2024 | -10.0% | -15.9% | -13.7% | |
| Q3 2024 | +2.0% | +1.8% | -17.9% | |
| Q2 2024 | +11.2% | +10.1% | +16.6% | |
| Q1 2024 | -2.2% | +1.8% | -0.8% | |
| Q4 2023 | -12.3% | -14.7% | -29.6% | |
| Q3 2023 | +1.2% | +5.8% | +10.6% | |
| Q2 2023 | -3.7% | -7.1% | -13.4% | |
| Q1 2023 | -7.5% | -7.9% | -9.2% | |
| Q4 2022 | -0.5% | +3.9% | +2.0% | |
| Q3 2022 | -10.6% | -7.7% | +28.6% | |
| Q2 2022 | +2.1% | +4.2% | -6.7% | |
| Q1 2022 | -2.8% | -5.4% | +3.7% | |
| Q4 2021 | -8.4% | -11.4% | -1.0% | |
| Q4 2019 | -8.4% | -11.4% | -1.0% | |
| Q3 2021 | -15.9% | -13.7% | -20.0% | |
| Q2 2021 | -0.7% | -6.3% | +1.0% | |
| Q2 2020 | -0.7% | -6.3% | +1.0% | |
| Q1 2021 | -5.4% | -3.4% | +3.5% | |
| Q1 2020 | -5.4% | -3.4% | +3.5% | |
| Q4 2020 | +8.9% | +13.6% | +1.4% | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro